Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
NCT02241720 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2018-01-11
Summary
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Conditions
- Upper GI Cancer
Interventions
- DRUG
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-05-31
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
NCT06206278 ·Status: TERMINATED ·Phase: PHASE2
-
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
NCT01178944 ·Status: COMPLETED ·Phase: PHASE2
-
Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07148427 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
NCT00080002 ·Status: TERMINATED ·Phase: PHASE2
-
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
NCT01260701 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT04609176 ·Status: UNKNOWN ·Phase: PHASE2
-
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
NCT06099821 ·Status: RECRUITING ·Phase: PHASE2
-
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
NCT00017043 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
NCT01757171 ·Status: COMPLETED ·Phase: PHASE2
-
Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer
NCT00961077 ·Status: UNKNOWN ·Phase: PHASE2
-
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229 ·Status: RECRUITING ·Phase: PHASE2
-
Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer
NCT03627728 ·Status: COMPLETED ·Phase: PHASE2
-
Metronomic Chemotherapy in Advanced Gastric Cancer
NCT02855788 ·Status: UNKNOWN ·Phase: PHASE2
-
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
NCT04263870 ·Status: UNKNOWN ·Phase: PHASE2
-
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
NCT00017056 ·Status: COMPLETED ·Phase: PHASE2
-
PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04098796 ·Status: UNKNOWN ·Phase: PHASE2
-
RegoNivo vs Standard of Care Chemotherapy in AGOC
NCT04879368 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
NCT05019794 ·Status: UNKNOWN ·Phase: PHASE2
-
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT04923932 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
NCT03276156 ·Status: UNKNOWN ·Phase: PHASE1
-
S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy
NCT02191566 ·Status: TERMINATED ·Phase: PHASE2
-
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
NCT02537171 ·Status: UNKNOWN ·Phase: PHASE3
-
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
NCT00005876 ·Status: UNKNOWN ·Phase: PHASE2
-
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT04631757 ·Status: UNKNOWN ·Phase: PHASE2
-
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
NCT03469557 ·Status: COMPLETED ·Phase: PHASE2